SOURCE: Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals, Inc.

September 04, 2009 10:12 ET

Molecular Insight Pharmaceuticals, Inc. to Present at Rodman and Renshaw 11th Annual Healthcare Conference

CAMBRIDGE, MA--(Marketwire - September 4, 2009) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) will make a presentation at the Rodman and Renshaw 11th Annual Healthcare Conference on September 10, 2009 at 2 PM, Eastern Daylight Time. Daniel L. Peters, President and Chief Executive Officer, will present an overview of the Company and its pipeline of targeted therapeutic and molecular imaging radiopharmaceuticals. The presentation will take place in the Fahnestock Salon, on the fifth floor of the New York Palace Hotel in New York, New York.

The presentation will be webcast live at http://www.wsw.com/webcast/rrshq15/mipi and will be archived for 90 days. The webcast also will be available in the Investor Relations section of the Molecular Insight Pharmaceuticals website at www.molecularinsight.com.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging in oncology and cardiology. Molecular Insight has five clinical-stage candidates in development. The Company's oncology candidates include: Azedra™ for treatment of pheochromocytoma and neuroblastoma, Onalta™ for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors, Solazed™, which targets malignant metastatic melanoma, and Trofex for the detection of metastatic prostate cancer. Zemiva™ is being developed for the diagnosis of acute myocardial ischemia. For further information on Molecular Insight Pharmaceuticals, please visit www.molecularinsight.com.

Contact Information